(Alliance News) - Biotechnology company Tiziana Life Sciences PLC on Monday reported a slightly narrowed loss in a "busy" six months.
Shares in Tiziana were down 8.7% at 47.00 pence in London on Monday.
Tiziana's pretax loss was GBP3.7 million in the six months to June 30, slightly improved from GBP3.9 million a year ago. This was a research & development costs fell to GBP1.5 million from GBP2.3 million, but operating expenses increased to GBP2.2 million from GBP1.6 million.
Looking ahead, Tiziana said it is confident it is well positioned to advance its programs to their next value inflection points.
Tiziana expects to commenced a phase 2 study for nasally administered Foralumab, a human engineered anti-CD3 monoclonal antibody, in the coming months. A phase 2b trial dosing lead small molecule drug Milciclib in combination with Sorafenib is due to start in the second half of 2019.
By Lucy Heming; lucyheming@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
